Lundbeck to buy Parkinson's drug developer in potential $1.1 billion deal

COPENHAGEN (Reuters) – Lundbeck agreed to buy Prexton Therapeutics, a specialist in treatments for brain disorders, in a deal potentially worth $1.1 billion, the Danish drugmaker said on Friday.

Source: Reuters Medical News